Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 156

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 2
Chunk 156
---
ing. Bot/Bal remains investigational and is not approved for commercial marketing in France or elsewhere.

On July 10, 2025, Pelthos announced the launch of Zelsuvmi, for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. Zelsuvmi received a Novel Drug designation from the FDA in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition.

37

Results of Operations

Revenue and Other Income

(Dollars in thousands)Q3 2025Q3 2024Change% ChangeYTD 2025YTD 2024Change% Change    Revenue from intangible royalty assets$40,161 $26,552 $13,609 51 %$91,832 $67,512 $24,320 36 %    Income from financial royalty assets6,425 5,157 1,268 25 %18,640 6,454 12,186 189 %Royalties46,586 31,709 14,877 47 %110,472 73,966 36,506 49 %Captisol10,672 6,255 4,417 71 %32,419 22,967 9,452 41 %Contract revenue and other income58,203 13,848 44,355 320 %65,530 27,388 38,142 139 %Total revenue and other income$115,461 $51,812 $63,649 123 %$208,421 $124,321 $84,100 68 %

Q3 2025 vs. Q3 2024

Total revenue and other income increased by $63.6 million, or 123%, to $115.5 million in Q3 2025 compared to $51.8 million in Q3 2024. 

Royalties increased by $14.9 million, or 47%, to $46.6 million in Q3 2025 compared to $31.7 million in Q3 2024, primarily due to increase in Filspari, Ohtuvayre and Capvaxive sales.

Captisol sales increased by $4